Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1283-1290

  Zhang, Wenxia ^a,b   Lim, Lee Yong ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYL METHYL DISULFIDE; CARYOPHYLLENE; CINEOLE; CITRAL; CURCUMIN; CYTOCHROME P450 3A4; DIGOXIN; GARLIC EXTRACT; GINGEROL; GLYCOPROTEIN P; LIMONENE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; MYRCENE;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CHIVE; CONTROLLED STUDY; CORIANDER; CURCUMA LONGA; CYMBOPOGON CITRATUS; DRUG CYTOTOXICITY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; ENZYME ACTIVITY; GENETIC TRANSFECTION; GINGER; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; MURRAYA; NONHUMAN; PRIORITY JOURNAL; SPICE;

ANIMALS; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; HUMANS; LLC-PK1 CELLS; MICROSOMES, LIVER; P-GLYCOPROTEINS; PROTEIN TRANSPORT; SPICES; SWINE;

ALLIUM SCHOENOPRASUM; CORIANDRUM SATIVUM; CURCUMA LONGA; CYMBOPOGON CITRATUS; SUS; ZINGIBER OFFICINALE;

EID: 46449099725     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019737     Document Type: Article

References (40)

1. Aggarwal BB and Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397-1421.
2. Anuchapreeda S, Leechanachai P, Smith M, Ambudkar SV, and Limtrakul P (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug resistant human KB cells. Biochem Pharmacol 64:573-582.
3. Artursson P. Karlsson J, Ocklind G, and Schipper N (1996) Studying transport processes in absorptive epithelia, in Epithelial Cell Culture: A Practical Approach (Shaw AJ ed) pp 111-133, New York, Oxford University Press.
4. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, and Fromm MF (2002) Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302:645-650.
5. Brazier NC and Levine MAH (2003) Drug-herb interactions among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10:163-169.
6. Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, Campbell AP, Kunze KL, and Nelson SD (2005) Cooperative binding of midazolam with testosterone and α-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44:14143-14151.
7. Cavet ME, West M, and Simmons NL (1996) Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118:1389-1396.
8. Demirbas S and Stavchansky S (2003) Effects of citicholine and dimethylsurfoxide on transepithelial transport of passively diffused drugs in the Caco-2 cell culture model. Int J Pharm 251:107-112.
9. Dundee JW, Halliday NJ, Harper KW, and Brogden RN (1984) Midazolam: a review of its pharmacologic properties and therapeutic use. Drugs 28:519-543.
10. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, and Kessler RC (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575.
11. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, and Choudri S (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4:176-184.
12. Fujita K, Ando Y, Narabayashi M, Miya T, Nagashima F, Yamamoto W, Kodama K, Araki K, Endo H, and Sasaki Y (2005) Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5- aminopentanoic acid)-1-piperidino]carbonyloxy-camptothecin from irinotecan. Drug Metab Dispos 33:1785-1790.
13. Galelin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190.
14. Good PD, Schneider JJ, and Ravenscroft PJ (2004) The compatibility and stability of midazolam and dexamethasone in infusion solutions. J Pain Symptom Manage 27:471-475.
15. Greiner B, Eichelhaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
16. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
17. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
18. Johnson BM, Charman WN, and Porter CJ (2003) Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab Dispos 31:1151-1160.
19. Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, and Liu KH (2006) Inhibitory effects of fruit juices on CYP3A activity. Drug Metab Dispos 34:521-523.
20. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 10:289-294.
21. Lawson DM (2003) A model for visualizing Quid handling by the gastrointestinal tract. Adv Physiol Educ 27:87-88.
22. McConnell EL, Basit AW, and Murdan S (2008) Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60:63-70.
23. Nabekura T, Kamiyama S, and Kitagawa S (2005) Effects of dietary chemopreventive phyto-chemicals on P-glycoprotein function. Biochem Biophys Res Commun 327:866-870.
24. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, and von Moltke LL (2005) Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764-770.
25. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsornes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628.
26. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, and Falloon J (2002) The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234-238.
27. Schinkel AH. Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
28. Schuetz EG, Beck WT, and Schuetz JD (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-resulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
29. Schuetz EG, Schinkel AH, Relling MV, and Schuetz JD (1996b) P-glycoprotein: a major determinant of rifampicin-inducihle expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 93:4001-4005.
30. Scudiero DA, Shoemaker RH, Paul KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, and Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
31. Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, and Rushmore TH (2001) A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256-2262.
32. Synold TW, Dassault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Mad 7:584-590.
33. Tanigawara Y, Okamura N. Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T. and Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
34. Tindle HA, Davis RB, Phillips RS, and Eisenherg DM (2005) Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 11:42-49.
35. Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, Ariyoshi N. Ohmori S, Igarashi T, and Kitada M (2003) Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42:15068-15077.
36. Wang WH, Wang ZM, Xu LZ, and Yang SL (2002) HPLC determination of 6-gingcrol in Rhizoma Zingiberis Recens. Zhongguo Zhang Yaa Za Zhi 27:348-349.
37. Wang YH, Jones DR, and Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664-671.
38. Watkins PB (1997) The hairier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
39. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, and Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204.
40. Zhang W, Tan MCT, and Lim LY (2007) Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110-115.